Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tandem Diabetes smashes IPO target

This article was originally published in Clinica

Executive Summary

Insulin pump developer Tandem Diabetes Care has not only successfully launched its initial public offering but the amount it raised exceeded expectations to boot. The company sold eight million shares at $15 each, the top end of its pricing range; the $120m it raised in total beat the $92-106m it had been hoping to get by selling 7.1 million shares at $13-15 each. Tandem’s achievement could perhaps allay fears that the medtech/biotech IPO window – which has been open for some time – may be starting to close.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel